Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DKN-01 and Atezolizumab in Advanced Biliary Tract and Esophagogastric Cancer
NCT03818997Phase 2Withdrawn
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- Dec 2019
- Primary completion
- Apr 2021
- Modality
- Monoclonal Antibodies
01
Overview
Phase 2, randomised, open-label trial of sirexatamab in biliary tract cancer (BTC) and Esophago-Gastric Adenocarcinoma (3 arms), sponsored by European Organisation for Research and Treatment of Cancer. Primary endpoint: Objective Response Rate at 6 months. Planned start Dec 2019; status: withdrawn.
02
Drugs
sirexatamab
03
Conditions
biliary tract cancer (BTC)Esophago-Gastric Adenocarcinoma
Beyond the preview
Go deeper on NCT03818997.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03818997.